Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus TRIACIN C.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus TRIACIN C.
KENALOG IN ORABASE vs TRIACIN-C
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
TRIACIN-C is a combination of triamcinolone (a corticosteroid) and nystatin (an antifungal). Triamcinolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Nystatin binds to ergosterol in fungal cell membranes, causing pore formation and cell death.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
5 mg orally twice daily, taken with meals to enhance absorption.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Terminal elimination half-life: 7–9 hours. In patients with severe hepatic impairment (Child-Pugh C), half-life may extend to 15 hours; dosing adjustment recommended.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Renal: ~60% as unchanged drug; hepatic metabolism accounts for ~25% (primarily via CYP3A4), with biliary excretion of metabolites (~15%); fecal elimination <5%.
Category C
Category C
Corticosteroid
Corticosteroid